Top-News
Gesundheitswesen USA

Lipocine News

Aktie
WKN:  A3EBZD ISIN:  US53630X2036 US-Symbol:  LPCN
4,97 $
+0,00 $
0,00%
03.05.24 16:14:59
Handeln Depot/Watchlist
Aktienanzahl *
5,21 Mio.
Marktkapitalisierung *
25,72 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 15.05.2023

Lipocine News

09.05.24 - PR Newswire
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 PR Newswire
08.05.24 - PR Newswire
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 PR Newswire
01.05.24 - PR Newswire
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 PR Newswire
11.04.24 - PR Newswire
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire
28.03.24 - PR Newswire
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire
25.03.24 - PR Newswire
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire
07.03.24 - PR Newswire
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire
06.03.24 - PR Newswire
Lipocine to Present at 36th Annual Roth Conference
Lipocine to Present at 36th Annual Roth Conference PR Newswire
06.02.24 - PR Newswire
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 PR Newswire
02.02.24 - PR Newswire
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals PR Newswire
18.01.24 - PR Newswire
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada PR Newswire
19.12.23 - PR Newswire
Lipocine to Present at Biotech Showcase 2024
Lipocine to Present at Biotech Showcase 2024 PR Newswire
13.11.23 - PR Newswire
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 PR Newswire
08.11.23 - PR Newswire
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 PR Newswire
01.11.23 - PR Newswire
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 PR Newswire
26.10.23 - PR Newswire
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression PR Newswire
23.10.23 - PR Newswire
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference PR Newswire
19.09.23 - PR Newswire
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
10.08.23 - PR Newswire
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire
27.07.23 - PR Newswire
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire

Newssuche

Videos

newspaper
07.05.24 -3,73%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »